Top Industry Leaders in the Omega 3 Prescription Drugs Market
October 2023:
Amarin Corporation's Vascepa (icosapent ethyl) received an expanded label from the FDA for the treatment of severe hypertriglyceridemia, including patients with mixed dyslipidemia (elevated LDL-C and triglycerides). This expanded indication could increase potential patient population for Vascepa.
December 2023:
EPA Therapeutics announced topline results from a Phase 3 trial (REDUCE-IT) showing that its prescription omega-3 drug, Epanova, did not meet the primary endpoint of reducing major adverse cardiovascular events (MACE) in a high-risk cardiovascular population already on statin therapy. However, the study did show some positive secondary outcomes, and further analysis is ongoing.
September 2023:
Amarin Corporation presented positive data from a Phase 4 study demonstrating the long-term safety and efficacy of Vascepa in reducing triglyceride levels and cardiovascular risk factors.
List of Omega 3 Prescription Drugs Key companies in the market-
Abbott
-
Amarin Pharmaceuticals Ireland Ltd.
-
GSK plc
-
Natrapharm, Inc. (Patriot Pharmaceutical Corp.)
-
Viatris Inc.
-
Grupo Ferrer Internacional, S.A.
-
Camber Pharmaceuticals, Inc.
-
Dr. Reddy’s Laboratories Ltd.
-
Zydus Group
-
Hikma Pharmaceuticals PLC
